Difference between revisions of "Team:ETH Zurich"

(Only target hyperlinks of main page (keep iGEM title intact).)
(Update landing page with Nico's texts.)
Line 5: Line 5:
 
{{ETH_Zurich/Head_N_Suffix}}
 
{{ETH_Zurich/Head_N_Suffix}}
 
{{ETH_Zurich/Header_N}}
 
{{ETH_Zurich/Header_N}}
−
 
 
<html>
 
<html>
−
 
−
<style>
 
−
 
−
main {
 
−
      font-size: 16px;
 
−
}
 
−
 
−
main a {
 
−
      font-weight: 900;
 
−
      color: #101010;
 
−
}
 
−
 
−
 
−
main a:visited {
 
−
      color: #101010;
 
−
}
 
−
 
−
img.banner {
 
−
      margin-top: 66px;
 
−
}
 
−
 
−
</style>
 
−
 
 
<main role="main">
 
<main role="main">
−
 
 
<div id="title">  
 
<div id="title">  
−
<figure>
+
     <a href="/Team:ETH_Zurich">
−
     <a href="https://2017.igem.org/Team:ETH_Zurich">
+
         <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png"/>
−
         <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png" class="banner">
+
 
     </a>
 
     </a>
−
</figure>
 
 
</div>
 
</div>
−
 
−
 
  
 
<a href="#start">
 
<a href="#start">
−
     <img class="scroll-ico" src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png" class="step">
+
     <img class="scroll-ico" src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png">
 
</a>
 
</a>
−
 
−
 
  
 
<section id="start" class="step">
 
<section id="start" class="step">
 +
    <h1>Why?</h1>
 
     <div>
 
     <div>
−
         Cancer kills over 8 million people every year. That's the entire population of Switzerland!
+
         <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
−
        <br>
+
         <p>We need more specific therapies because current approaches result in many side-effects.</p>
−
         <br>
+
        <p>Thats why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.
−
        We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one  
+
         <!-- NOTE: I think this paragraph is a bit cheesy. -->
−
        living cancer therapeutic with an integrated two-step safety mechanism. That's why we created CATE: Cancer-Targeting <i>E. coli</i>.  
+
         <p>A living cure to a living disease!</p>
−
         <br>
+
−
         <br>
+
−
        A living cure to a living disease.
+
−
        <br>
+
−
        <br>
+
−
        <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Background</a>
+
 
     </div>
 
     </div>
−
 
+
     <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH">
−
     <figure>
+
    <a href="/Team:ETH_Zurich/Background" class="more">Background</a>
−
        <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" style="float:right;width: 370px;height:auto;">
+
−
    </figure>
+
−
   
+
 
</section>
 
</section>
−
 
−
 
  
 
<section id="second" class="step invert">
 
<section id="second" class="step invert">
−
 
 
     <div>
 
     <div>
−
      CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors.  
+
        <p>CATE consists of the non-pathogenic bacterium  <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors.</p>
−
      <br>
+
        <p>We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p>
−
      <br>
+
−
        It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.
+
−
      <br>
+
−
      <br>
+
−
      <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Description</a>
+
 
     </div>
 
     </div>
−
      
+
     <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec">
−
    <figure>
+
    <a href="/Team:ETH_Zurich/Description" class="more">Project description</a>
−
        <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" style="float:left;width: 240px;height:auto;">
+
−
    </figure>
+
−
 
+
 
</section>
 
</section>
  
 
<section id="third" class="step">
 
<section id="third" class="step">
 
     <div>
 
     <div>
−
      CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have gathered at the tumor, they make themselves visible and prepare a  
+
        <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p>
−
      payload. A doctor can then control the site with an MRI and activate release of the cancer-killing payload.
+
        <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p>
−
      <br>
+
−
      <br>
+
−
      <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Treatment</a>
+
 
     </div>
 
     </div>
−
 
+
    <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND">
 +
    <!-- TODO: Fix the following link -->
 +
    <a href="/Team:ETH_Zurich/#" class="more">Design</a>
 
</section>
 
</section>
−
 
−
    <center>
 
−
      <figure>
 
−
          <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND" style="width: 600px;height:auto;padding-bottom:15px;">
 
−
      </figure>
 
−
    </center>
 
−
 
 
<section>
 
<section>
−
      To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules. All functions were tested and optimized to  
+
    <h1>Vision</h1>
−
        make the resulting circuit as safe and well characterized as possible.
+
    <div>
−
      <br>
+
    <p>CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors. It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.</p>
−
      <br>
+
    </div>
−
      <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Circuit</a>
+
    <a href="/Team:ETH_Zurich/Description" class="more">Description</a>
 
</section>
 
</section>
−
 
+
<section>
−
<section id="second" class="step invert">
+
    <h1>Treatment</h1>
−
  <div>
+
    <div>
−
  </div>
+
<p>CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have gathered at the tumor, they make themselves visible and prepare a payload. A doctor can then control the site with an MRI and activate release of the cancer-killing payload. -> Treatment
 +
    <a href="/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a>
 +
</section>
 +
<section>
 +
    <h1>Circuit</h1>
 +
    <div>
 +
<p>To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules. All functions were tested and optimized to make the resulting circuit as safe and well characterized as possible.</p>
 +
    </div>
 +
    <a href="/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a>
 +
</section>
 +
<section>
 +
    <h1>Engineering: Dry Lab</h1>
 +
    <div>
 +
        <p>We increased the understanding of the systems underlying mathematics by simulating the functions with models. The models were also used to define important questions to clarify in experiments.</p>
 +
    </div>
 +
    <a href="/Team:ETH_Zurich/Model" class="more">Model</a>
 +
</section>
 +
<section>
 +
    <h1>Engineering: Wet Lab</h1>
 +
    <div>
 +
        <p>Experimentally, we collected data to support and refine our models and to show that our system works.</p>
 +
    </div>
 +
    <a href="/Team:ETH_Zurich/Results" class="more">Results</a>
 +
</section>
 +
<section>
 +
    <p>We worked goal oriented and could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action. We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.</p>
 +
    <a href="/Team:ETH_Zurich/Achievements" class="more">Achievements</a>
 +
</section>
 +
<section>
 +
    <h1>Team</h1>
 +
    <div>
 +
        <p>We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.</p>
 +
    </div>
 +
    <a href="/Team:ETH_Zurich/Members" class="more">The Team</a>
 
</section>
 
</section>
−
 
−
 
−
 
 
</main>
 
</main>
−
 
−
 
 
<script>
 
<script>
 
$(function() {
 
$(function() {
Line 132: Line 102:
 
         });
 
         });
 
</script>
 
</script>
−
 
−
 
 
</html>
 
</html>
 
{{ETH_Zurich/Footer_N}}
 
{{ETH_Zurich/Footer_N}}

Revision as of 13:48, 19 October 2017

Why?

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.

Thats why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.

A living cure to a living disease!

Background

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home preferentially in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description

CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor

The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.

Design

Vision

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors. It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.

Description

Treatment

CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have gathered at the tumor, they make themselves visible and prepare a payload. A doctor can then control the site with an MRI and activate release of the cancer-killing payload. -> Treatment Treatment

Circuit

To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules. All functions were tested and optimized to make the resulting circuit as safe and well characterized as possible.

Treatment

Engineering: Dry Lab

We increased the understanding of the systems underlying mathematics by simulating the functions with models. The models were also used to define important questions to clarify in experiments.

Model

Engineering: Wet Lab

Experimentally, we collected data to support and refine our models and to show that our system works.

Results

We worked goal oriented and could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action. We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.

Achievements

Team

We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.

The Team